Cancer
Lung cancer in Tianjin
天津 肺癌
7 hospitals in Tianjin
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Tianjin may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 258 papers led
- 124 papers ledNo open trial led
- 39 papers ledNo open trial led
- 30 papers ledNo open trial led
- 26 papers led
- 19 papers led
- 8 papers ledNo open trial led
Lung cancer in every city Tianjin on the disease page, with the national map
open trials on lung cancer with a hospital in Tianjin
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Tianjin as lead sponsor or study site. 35 of them are led by a hospital in Tianjin. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07195695
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
- RecruitingStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07288177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingA Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07358676
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07367529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07472517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
- RecruitingHippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07505173
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingDownstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07528066
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingMicrowave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07528274
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07541170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin
- RecruitingRATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07541521
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingA Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07548060
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingFeasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07561567
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07586202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
- RecruitingStudy of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07589205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07622186
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study of DS-3939a in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07739966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou
- RecruitingNK Cells Plus ICI for SCLC Maintenance
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07759856
Age 18 years to Not stated (registered criteria)
Led by Tianjin First Central HospitalTianjin
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingPhase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06773507
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06801834
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingSecond-line Immunotherapy for ES-SCLC
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06853678
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT06868485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Shanghai, Tianjin, Wuhan
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06890598
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingCryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06939127
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingA Study of SKB518 in Patients With Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07019675
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou
- RecruitingElectroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07034326
Age 18 years to 80 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingSpatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07058948
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteBeijing, Tianjin
- RecruitingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07079475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin
- RecruitingElectroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07086300
Age 65 years to 100 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingPhase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07087223
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 7 listed hospitals as study sitesBeijing, Dalian, Shijiazhuang, Tianjin
- RecruitingA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07111520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- RecruitingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07143045
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07154706
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07206498
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Shanghai, Tianjin
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingElectroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07239661
Age 18 years to Not stated (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingFurmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07304739
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingTALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07330037
Age 17 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07330050
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Luoyang, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06203210
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingTo Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06352008
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingOsimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06363734
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416410
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou
- RecruitingA Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06417008
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin
- RecruitingA Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06496490
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi
- RecruitingEffect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06548711
Age 18 years to 80 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06561386
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingStudy of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06567015
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin
- RecruitingPhase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06621563
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingSpatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06775678
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05913089
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06119581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang
- RecruitingPhase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06123754
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingPhase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT06141226
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingMediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
- Phase
- N/A
- Started
- 2022-05
- Posted
- Registry
- NCT04631770
Age not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05498428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingOsimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
- Phase
- Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05686434
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai
- RecruitingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Posted
- Registry
- NCT04270591
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- Not yet recruitingToripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07358689
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingFurmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07365410
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingIparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07379398
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingA Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07601048
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingPhase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07670715
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingThiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07778940
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingLow-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07909863
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06885840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingOpen-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07172412
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingAnalysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07179445
Age 18 years to 100 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingSac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07244926
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-12
- Posted
- Registry
- NCT06704620
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingA Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-07
- Posted
- Registry
- NCT05940116
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Not yet recruitingPenpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT04846634
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteNanchang, Tianjin
- Enrolling by invitationSingle-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07916129
Age 18 years to 85 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Enrolling by invitationPersonalized SBRT in Early-Stage Peripheral NSCLC
- Phase
- Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT07167459
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Tianjin
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Logistics University of Chinese People中国人民武装警察部队特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beichen District Tradicine Chinese Medicine Hospital天津市北辰区中医医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Cangzhou Central Hospital沧州市中心医院 | 2 | none | none | 11 | 30 | none | 20 | 14 | none | 0 | none | 7 | 1 | 2 | 1 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 6 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Nankai University天津市人民医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Teaching Hospital, Tianjin University of Traditional Chinese Medicine天津中医药大学第一附属医院 | none | none | none | none | 264 open | none | 54 open | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Haihe Hospital天津市海河医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所) | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 4728 open | 1312 open | 489 open | none | 3432 open | 1 | 255 open | none | 0 | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Pingjin Hospital平津医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine天津中医药大学第二附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Hospital of Tianjin Medical University天津医科大学第二医院 | none | none | none | 3 | 8 | none | none | none | none | none | none | 0 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 23 | 4 | none | none | none | none | 1 | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| TEDA International Cardiovascular Hospital泰达国际心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 15 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| TEDA International Cardiovascular Hospital泰达国际心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Baodi Hospital天津市宝坻区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Chest Hospital天津市胸科医院 | none | none | none | none | 39 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 362 open | 4 | none | none | none | none | 3 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Children's Hospital天津市儿童医院 | none | none | none | none | none | none | none | none | 2 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 17 | none | none | none | none | none | none | none | none | none | none | 0 | none | 2 | none | none | 0 | none | none | none | none | none | 1 | 2 | none | none | none | none | none | none | none | |
| Tianjin Eye Hospital天津市眼科医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Fifth Central Hospital天津市第五中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin First Central Hospital天津市第一中心医院 | none | none | 45 | none | 191 open | none | none | none | 1 | none | 1 | 3 | 0 | 0 | none | 8 | 2 | none | none | 21 | none | none | none | 0 | none | none | none | none | none | none | 9 | 3 | 3 | none | none | 1 | none | 2 | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Fourth Central Hospital天津市第四中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Hospital天津市天津医院 | none | none | none | none | none | none | none | none | none | none | none | 10 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | 1 | none | none | none | none | none | none | 0 | none | 1 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Huanhu Hospital天津市环湖医院 | none | none | none | none | none | none | none | 151 open | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 12 open | none | 02 open | none | none | none | none | none | none | 2 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Jinnan Hospital天津市津南医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University Baodi Hospital天津医科大学附属宝坻医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院 | 7 | 4712 open | 8811 open | 786 open | 25830 open | 7112 open | 24617 open | 14 | 1 | none | 1 | 18 | 2 | 211 open | 1 | 101 open | none | none | none | 569 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Tianjin Medical University Eye Hospital天津医科大学眼科医院 | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University General Hospital天津医科大学总医院 | 1 | 5 | 22 | 30 | 124 | 10 | 20 | 783 open | 1 | 1 | none | 3 | 2 | 0 | none | 271 open | 01 open | 23 | none | 71 open | none | none | none | 1 | none | 222 open | 3 | 211 open | 2 | none | none | 16 | 1 | none | none | 0 | none | 7 | none | 1 | 1 | none | none | 2 | none | 1 | 10 | none | none | 4 | 7 | 1 | none | 0 | none | none | 0 | 3 | none | none | none | |
| Tianjin Nankai Hospital天津市南开医院 | none | none | none | none | none | 7 | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Port Hospital天津港口医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Second People's Hospital天津市第二人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Third Central Hospital天津市第三中心医院 | none | none | 30 | none | none | none | none | none | none | none | none | 0 | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Traditional Chinese Medicine Affiliated Hospital天津市中医药研究院附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Tianjin.
- Neuroblastoma 1
- Multiple myeloma 4728 open
- B-cell acute lymphoblastic leukaemia 1312 open
- Aplastic anaemia 489 open
- Lymphoma 3432 open
- Beta thalassaemia 1
- Haemophilia A 255 open
- Thrombotic thrombocytopenic purpura 0
- Fanconi anaemia 3
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Gaucher disease 0
- Primary sclerosing cholangitis 1
- Hepatocellular carcinoma 45
- Lung cancer 191 open
- Hepatoblastoma 1
- Chordoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 0
- Neuroblastoma 0
- Multiple myeloma 8
- B-cell acute lymphoblastic leukaemia 2
- Lymphoma 21
- Thrombotic thrombocytopenic purpura 0
- Biliary atresia 9
- Coronary heart disease 3
- Congenital heart disease 3
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 7
- Oesophageal squamous cell carcinoma 4712 open
- Hepatocellular carcinoma 8811 open
- Stomach cancer 786 open
- Lung cancer 25830 open
- Pancreatic cancer 7112 open
- Breast cancer 24617 open
- Glioma 14
- Hepatoblastoma 1
- Chordoma 1
- Osteosarcoma 18
- Gastrointestinal stromal tumour 2
- Neuroblastoma 211 open
- Ewing sarcoma 1
- Multiple myeloma 101 open
- Lymphoma 569 open
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 22
- Stomach cancer 30
- Lung cancer 124
- Pancreatic cancer 10
- Breast cancer 20
- Glioma 783 open
- Hepatoblastoma 1
- Retinoblastoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Multiple myeloma 271 open
- B-cell acute lymphoblastic leukaemia 01 open
- Aplastic anaemia 23
- Lymphoma 71 open
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 222 open
- IgG4-related disease 3
- Myasthenia gravis 211 open
- Moyamoya disease 2
- Coronary heart disease 16
- Congenital heart disease 1
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 1
- Duchenne muscular dystrophy 2
- Alport syndrome 1
- IgA nephropathy 10
- Osteogenesis imperfecta 4
- Primary biliary cholangitis 7
- Primary sclerosing cholangitis 1
- Hirschsprung disease 0
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 3
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lung cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Tianjin on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.